ELISA reagent kit for screening suspected patient with immunity correlated disease
A technology of immune-related diseases and enzyme-linked immunosorbent reagents, which is applied in the field of enzyme-linked immunosorbent immunoassay kits, and can solve problems such as induction
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment 1
[0063] Example 1. Target proteins recognized by anti-activated T cell antibodies are calreticulin (CRT), ERp57 and vimentin
[0064] In the process of studying the mechanisms of TCV-induced immune regulation, people have gained a better understanding of TCV-induced regulatory T cell responses, but little is known about TCV-induced specific humoral responses (ie, antibodies). In the present invention, the ovalbumin (OVA)-specific T cell line derived from BALB / c mice was used as a vaccine to immunize mice of the same strain, and it was found that TCV could induce a humoral immune response against activated T cells. This result reveals the existence of anti-T cell regulatory antibodies, lays the foundation for future research on regulatory anti-T cell antibodies (regulatory anti-T-cell Abs), and also proposes a new approach for the treatment of immune-related diseases through this approach. New strategies and methods.
[0065] 1. Establishment of OVA-specific T cell lines
[00...
Embodiment 2
[0102] Example 2, ELISA kit for screening suspected patients with immune-related diseases
[0103] The present invention develops CRT, ERp57 and Vimentin specific antibody detection ELISA kit, and uses it to measure serum antibodies of chronic hepatitis B patients, rheumatoid arthritis patients and SLE patients.
[0104] 1. The composition of the kit
[0105] The composition of the kit is mainly composed of calreticulin-1, ERp57-1 or vimentin-coated ELISA plates, and also contains anti-HRP-labeled human or mouse IgG, and various reagent solutions for conventional ELISA detection: washing solution, substrate solution and stop solution.
[0106] Wherein, calreticulin-1, ERp57-1 or vimentin recombinant protein is coated with the microtiter plate according to the following method: use coating solution (0.05M pH9.6 carbonate buffer) to calreticulin-1, ERp57-1 or vimentin recombinant protein Dilute to 0.1-1 μg / ml respectively, add 100 μl to each well, incubate at 37°C for 2 hours,...
PUM
Login to View More Abstract
Description
Claims
Application Information
Login to View More 